

WHAT IS CLAIMED IS:

1. A process of administering to a mammal in need of such administration, for the purpose of eradicating *H. pylori* bacteria in the stomach of the mammal, a carbonic anhydrase inhibitor drug.
2. A process in accordance with Claim 1 wherein the mammal is a human being.
3. A process in accordance with Claim 2 where the drug is a sulfonamide.
4. A process in accordance with Claim 3 where the drug is selected from the group consisting of acetazolamide, dorzolamide and brinzolamide.
5. A process in accordance with Claim 4 where the drug is acetazolamide.
6. A process in accordance with Claim 1 where the drug is administered in a daily dose that results in a 4×10^{-4} to 4×10^{-9} M concentration of the drug in the mammal's stomach.
7. A process in accordance with Claim 6 wherein the mammal is a human being.
8. A process in accordance with claim 1 where a daily dose of 5 mg to 30 mg per kg body weight of the mammal is administered.
9. A process in accordance with Claim 8 wherein the mammal is a human being.
10. A process of administering to a human in need of such administration, for the purpose of eradicating *H. pylori* bacteria in the human's stomach a carbonic anhydrase inhibitor drug in a daily dose that results in a 4×10^{-4} to 4×10^{-9} M concentration of the drug in the human's stomach.
11. A process in accordance with Claim 10 where the drug is a sulfonamide.
12. A process in accordance with Claim 11 where the drug is selected from the group consisting of acetazolamide, , dorzolamide and brinzolamide.
13. A process in accordance with Claim 12 where the drug is

acetazolamide.

14. A process in accordance with claim 10 where a daily dose of 5 mg to 30 mg per kg body weight of the human is administered.

15. A process in accordance with Claim 14 where the drug is a sulfonamide.

16. A process in accordance with Claim 15 where the drug is selected from the group consisting of acetazolamide, dorzolamide and brinzolamide.

17. A process in accordance with Claim 16 where the drug is acetazolamide.

18. A pharmaceutical composition comprising a carbonic anhydrase inhibitor drug in a quantity that with administration of a daily dose results in a 4×10^{-4} to 4×10^{-9} M concentration of the carbonic anhydrase inhibitor drug in the stomach of a mammal, the composition being for the purpose of eradicating *H. pylori* bacteria in the stomach of the mammal.

19. A pharmaceutical composition in accordance with Claim 18 where the drug is a sulfonamide.

20. A pharmaceutical composition in accordance with Claim 19 where the drug is selected from the group consisting of acetazolamide, dorzolamide and brinzolamide.

21. A pharmaceutical composition in accordance with Claim 20 where the drug is acetazolamide.